Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Sees Large Increase in Short Interest

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 6,430,000 shares, an increase of 21.3% from the October 31st total of 5,300,000 shares. Based on an average daily trading volume, of 459,500 shares, the days-to-cover ratio is presently 14.0 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RVPH. Benchmark reiterated a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a report on Monday, August 26th. EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Finally, Maxim Group reiterated a “hold” rating on shares of Reviva Pharmaceuticals in a report on Friday, August 16th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent reporting period. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Trading Up 8.8 %

Shares of NASDAQ RVPH opened at $1.24 on Monday. The business has a fifty day simple moving average of $1.20 and a 200 day simple moving average of $1.20. The firm has a market capitalization of $41.47 million, a price-to-earnings ratio of -1.12 and a beta of -0.05. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $5.67.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.